BIOMAT Database Logo BIOMAT Database Logo

Predictors of postprandial blood glucose response to biphasic insulin analogue therapy. 2013

Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Department of Internal Medicine, Vittorio Emanuele Hospital, Catania, Italy. vitoborzi@gmail.com

Biphasic insulin aspart 30 (BIAsp 30) has been shown in randomised controlled trials and the IMPROVE™ observational study to reduce postprandial blood glucose (PPBG) - thought to be an independent risk factor for cardiovascular disease. We used multivariate regression analysis to identify predictors of PPBG reduction in the IMPROVE™ study. A total of 52,419 type 2 diabetes patients were enrolled in the IMPROVE™ study (pre-study therapy subgroups: no pharmaceutical therapy, n = 8966; oral antidiabetic drugs [OADs] only, n = 33,797; insulin ± OADs, n = 9568; missing information on pre-study therapy, n = 88). Mean change from baseline in PPBG (mean of three meals) in the global cohort was -6.3 mmol/L; reductions in subgroups were: no pharmaceutical therapy, -8.8 mmol/L; OADs only, -6.0 mmol/L; insulin ± OADs, -5.1 mmol/L. High baseline PPBG was consistently and strongly predictive of PPBG response; lower baseline HbA1c and body mass index, greater age and shorter diabetes duration were also significant predictors of PPBG change. The novel findings from this study indicate that most patients can be expected to achieve a PPBG response with BIAsp 30 irrespective of baseline characteristics or previous therapy with an expected larger PPBG reduction when baseline PPBG is higher.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D007336 Insulin, Isophane An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn. Insulin, NPH,Insulin, Protamine Zinc,Isophane Insulin, Regular,NPH Insulin,Neutral Protamine Hagedorn Insulin,Protamine Hagedorn Insulin,Hagedorn Insulin, Protamine,Isophane Insulin,Protamine Zinc Insulin,Regular Isophane Insulin,Zinc Insulin, Protamine
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006442 Glycated Hemoglobin Products of non-enzymatic reactions between GLUCOSE and HEMOGLOBIN (occurring as a minor fraction of the hemoglobin of ERYTHROCYTES.) It generally refers to glycated HEMOGLOBIN A. Hemoglobin A1c (Hb A1c) is hemoglobin A with GLYCATION on a terminal VALINE of the beta chain. Glycated hemoglobin A is used as an index of the average blood sugar level over a lifetime of erythrocytes. Fructated Hemoglobins,Glycohemoglobin,Glycohemoglobin A,Glycohemoglobins,Glycosylated Hemoglobin A,Hb A1c,HbA1,Hemoglobin A(1),Hemoglobin A, Glycosylated,Glycated Hemoglobin A,Glycated Hemoglobin A1c,Glycated Hemoglobins,Glycosylated Hemoglobin A1c,Hb A1,Hb A1a+b,Hb A1a-1,Hb A1a-2,Hb A1b,Hemoglobin, Glycated A1a-2,Hemoglobin, Glycated A1b,Hemoglobin, Glycosylated,Hemoglobin, Glycosylated A1a-1,Hemoglobin, Glycosylated A1b,A1a-1 Hemoglobin, Glycosylated,A1a-2 Hemoglobin, Glycated,A1b Hemoglobin, Glycated,A1b Hemoglobin, Glycosylated,Glycated A1a-2 Hemoglobin,Glycated A1b Hemoglobin,Glycosylated A1a-1 Hemoglobin,Glycosylated A1b Hemoglobin,Glycosylated Hemoglobin,Hemoglobin A, Glycated,Hemoglobin A1c, Glycated,Hemoglobin A1c, Glycosylated,Hemoglobin, Glycated,Hemoglobin, Glycated A1a 2,Hemoglobin, Glycosylated A1a 1,Hemoglobins, Fructated,Hemoglobins, Glycated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Management of postprandial glucose: Recommended targets and treatment with biphasic insulin.
December 2016, Primary care diabetes,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose.
February 2008, Endocrinology,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Comment on "Management of postprandial glucose: Recommended targets and treatment with biphasic insulin".
December 2016, Primary care diabetes,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
April 2021, Diabetes, obesity & metabolism,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
[Factors and regulation of postprandial blood glucose response].
March 2006, Wei sheng yan jiu = Journal of hygiene research,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
March 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
An analogue computer model for the insulin response to glucose infusion.
May 1967, Acta endocrinologica,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration.
May 1990, Diabetes,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
May 2002, Diabetes care,
Vito Borzì, and Marian Benroubi, and Janusz Gumprecht, and Ryuzo Kawamori, and Robert Ligthelm, and Joseph Shaban, and Siddharth Shah, and Marina Shestakova, and Yang Wenying, and Paul Valensi, and
Influence of antecedent carbohydrate intake on the biphasic insulin response to intravenous glucose.
December 1975, Diabetes,
Copied contents to your clipboard!